Saved in:
| Format: | Artículo Open Access |
|---|---|
| Published: |
Wiley
2024
|
| Subjects: | |
| Online Access: | https://onlinelibrary.wiley.com/doi/10.1002/cpu30848 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Update: Reports of suicidality in patients taking diabetes/obesity medicines The Brown University Child & Adolescent Psychopharmacology Update The below is from a January 11 Drug Safety Communication from the U.S. Food and Drug Administration (FDA) evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs). The initial evaluation found that there is no evidence of a link between these medicines and suicidality. Below is the FDA's report. 10.1002/cpu30848 http://onlinelibrary.wiley.com/termsAndConditions#vor